A Phase 2 interventional study of Inhaled Human Insulin and Insulin Lispro (Humalog U-100) in Type 2 Diabetes Mellitus, sponsored by Dance Biopharm Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Dance Biopharm Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is the only one that started in 2018, is one of 8 in phase 2, and was the 46th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 26 · Phase 4 7
First in 1999; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 129 across the 49 interventional studies. Of the 46 that completed or were terminated, 11 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 49 have an industry lead sponsor. The 10 most frequent:
Dance Biopharm Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Dance Biopharm Inc. has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
To assess the dose-response and dose-exposure of Dance 501 (Human Insulin Inhalation Solution) administered with the Dance 501 Inhaler.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered using the Dance 501 Inhaler.
Drug: Inhaled Human Insulin
Insulin Lispro (Humalog®) will be administered by subcutaneous injection.
Drug: Insulin Lispro (Humalog U-100)
Dance 501 administered using the Dance 501 Inhaler
Also known as: Dance 501
Lispro
Also known as: Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Primary Pharmacokinetic Endpoint - PK 1
Area under the human insulin and insulin lispro concentrations time curves
Time frame: 0 - 10 hours
Primary Pharmacokinetic Endpoint - PK 2
Maximum observed concentration of human insulin and insulin lispro
Time frame: 0 - 10 hours
Primary Pharmacodynamic Endpoint - PD 1
Area under the glucose infusion rate time curve
Time frame: 0 - 10 hours
Primary Pharmacodynamic Endpoint - PD 2
Maximum observed glucose infusion rate
Time frame: 0 - 10 hours
Secondary Pharmacokinetic Endpoint - PK 1
Area under the insulin time curves at different intervals
Time frame: 0 - 1 hour, 0 - 2 hours, 0 - 8 hours
Secondary Pharmacokinetic Endpoint - PK 2
Time to maximum insulin concentrations
Time frame: 0 - 10 hours
Secondary Pharmacokinetic Endpoint - PK 3
Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro
Time frame: 0 - 10 hours
Secondary Pharmacokinetic Endpoint - PK 4
Onset of appearance (time from trial product administration until the serum insulin concentrations are \> LLOQ.
Time frame: 0 - 10 hours
Secondary Pharmacokinetic Endpoint - PK 5
Mean residence time of insulin
Time frame: 0 - 10 hours
Secondary Pharmacodynamic Endpoint - PD 1
AUC for GIR at different time intervals
Time frame: 0 - 1 hour, 0 - 2 hours, 0 - 8 hours
Secondary Pharmacodynamic Endpoint - PD2
Time to maximum glucose infusion rate
Time frame: 0 - 10 hours
Secondary Pharmacodynamic Endpoint - PD3
Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro
Time frame: 0 - 10 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Aug 2018, 3 months.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 3 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin, Regular, Human
Dance Biopharm Inc.